Thyroid Function on Steroids: Why Your T3 Looks Low

You get your mid-cycle bloodwork back and total T3 is flagged low. Red text. Below range. Your first thought: "Am I hypothyroid now?"

Probably not. And if you start thyroid medication based on that number alone, you could be treating a problem that does not exist.

This is one of the most common bloodwork misreads in the bodybuilding community. Anabolic steroids reliably suppress a protein called TBG (thyroxine-binding globulin), which drags total T3 and total T4 below reference ranges. But your actual thyroid function, measured by free T3, free T4, and TSH, is almost certainly fine.

Here is exactly what is happening, which markers to trust, and when you genuinely need to worry. (If you are new to bloodwork interpretation, start with our complete guide to bloodwork for bodybuilders first.)

How Steroids Affect Your Thyroid Panel

The key player is thyroxine-binding globulin (TBG), a carrier protein made by your liver. About 75% of the T4 and T3 circulating in your blood is bound to TBG. Only the unbound "free" fraction is biologically active.

Androgens suppress TBG production in the liver. Less TBG means less total hormone bound in circulation, so total T3 and total T4 drop. But free T3 and free T4, the fractions your cells actually use, stay within normal limits because your pituitary adjusts TSH output to compensate.

This is not hypothyroidism. It is a binding protein artifact.

The Evidence

Deyssig and Weissel (1993) measured 13 male bodybuilders using roughly 1.2 g/week of AAS for at least six weeks. TBG, total T3, and total T4 were all significantly decreased (P < 0.001). Basal TSH and free T4 showed no significant difference from non-using controls (Deyssig & Weissel, 1993).

The same pattern appeared in a stanozolol study: 10 mg/day orally for 14 days dropped total T4 and total T3 in lockstep with TBG, while TSH and free T4 stayed normal. All changes reversed after stopping (Small et al., 1984).

How much can TBG drop? In women treated with the synthetic androgen danazol, TBG fell to roughly one-third of baseline, a 67% decrease. Despite this dramatic reduction, patients remained euthyroid throughout (Thorell et al., 1979).

Oral Steroids Hit TBG Harder

Oral 17-alpha alkylated compounds like Dianabol, Anadrol, Winstrol, and Anavar pass through the liver on first pass, directly suppressing TBG synthesis. Injectable esters like testosterone enanthate also reduce TBG, but with less direct hepatic impact.

A 1965 comparison found that methandrostenolone and oxymetholone suppressed TBG as much as or more than methyltestosterone, despite being less androgenic (Olvey et al., 1965). TBG suppression is driven by hepatic first-pass effect, not androgenic potency.

What About Trenbolone?

There is no published head-to-head comparison of trenbolone versus testosterone on TBG in humans. Trenbolone's high androgen receptor affinity does not automatically translate to greater TBG suppression, since the effect is hepatic, not receptor-potency-driven. What we do know: non-aromatizing androgens like trenbolone lack the estrogenic counter-signal that upregulates TBG. Without estrogen offsetting the androgenic suppression, total T3 and T4 readings during a trenbolone run will likely appear lower than on a standard testosterone cycle.

Androgens vs. Corticosteroids: Two Different Mechanisms

If you search "do steroids affect thyroid," most results lump anabolic steroids and corticosteroids into one category. The mechanisms are completely different, and confusing them leads to wrong conclusions.

Anabolic androgenic steroids (AAS):

• Suppress TBG in the liver
• Lower total T3 and total T4
• Free T3, free T4, and TSH remain normal
• The thyroid itself is not impaired

Corticosteroids (prednisone, dexamethasone):

• Suppress TSH centrally (Wilber & Utiger, 1969)
• Block T4-to-T3 conversion peripherally via inhibition of type 1 deiodinase (Heyma & Larkins, 1982)
• Both active thyroid hormones are affected, not just transport proteins
• Can cause genuine functional hypothyroidism

If you are using dexamethasone for a joint flare or prednisone for allergies alongside your cycle, your thyroid panel is being hit by two separate mechanisms simultaneously. In that scenario, free T3 and free T4 can genuinely drop, not just total values.

Exogenous T3 (Cytomel) in Contest Prep

Many competitors use T3 (liothyronine/Cytomel) during contest prep to offset the metabolic slowdown from aggressive dieting. This is where thyroid bloodwork gets genuinely complicated.

How T3 Shuts Down Your Axis

A single 50 mcg dose of T3 suppresses TSH within 2 hours, with TSH reaching its lowest point around 12 hours post-dose (Jonklaas et al., 2015). On chronic use, your pituitary stops producing TSH entirely, and your thyroid stops making its own T4.

A case report in BMJ Case Reports described a bodybuilder using just 25 mcg/day of T3 for four weeks who presented with free T4 below the detectable threshold (under 5.2 pmol/L), TSH under 0.01 mU/L, and elevated free T3 at 7.5 pmol/L. His resting heart rate was 123 bpm and the initial diagnosis was sepsis. Thyroid function took eight months to fully normalize (Warner et al., 2020).

The Contest Prep "Perfect Storm"

During a hard cut, multiple factors stack on top of each other:

1. Caloric restriction alone reduces T3 by up to 53%. A zero-carbohydrate diet dropped T3 by 47% (Spaulding et al., 1976). In obese women on VLCDs, low-carbohydrate diets produced a 35% mean T3 decrease versus 18% for higher-carbohydrate VLCDs (Mathieson et al., 1986). This is "low T3 syndrome," driven by reduced peripheral deiodinase activity, not thyroid gland failure.

2. AAS suppress TBG, making total T3 appear even lower than the diet-induced reduction alone.

3. Exogenous T3 shuts down endogenous production entirely.

4. Elevated cortisol from the caloric deficit further blocks T4-to-T3 conversion.

Post-show, all four stressors resolve at different rates, creating an unpredictable recovery window.

The Growth Hormone Interaction

If you are running GH alongside T3, there is an important interaction. GH upregulates type 2 deiodinase (DIO2), the enzyme that converts T4 to T3 in peripheral tissues. In GH-deficient adults given escalating doses, free T3 increased in a dose-dependent manner while reverse T3 fell (Jorgensen et al., 1994).

GH is amplifying T4-to-T3 conversion on top of whatever exogenous T3 you are taking. Athletes on GH may need less exogenous T3 than they think. Ignoring this interaction risks compounding the suppressive effects and making the post-cycle rebound worse.

Tapering Off T3

Stopping T3 abruptly after weeks of use leaves you with zero endogenous T4 production and a suppressed pituitary. The result is transient but real hypothyroidism that can last weeks.

After chronic thyroid hormone therapy, mean TSH recovery took 16 days, but full T3 and T4 responses did not normalize until roughly 22 days post-withdrawal (Krugman et al., 1975).

Recommended taper: Reduce by 12.5 mcg every 5-7 days. If you are on 50 mcg/day, that means roughly 3 weeks of tapering before full discontinuation. Do not retest thyroid panels until at least 6 weeks after your last T3 dose.

The Overlooked Risk: Steroid-Induced Hyperthyroidism

Most of this article explains why low thyroid numbers on AAS are benign. But there is a documented, rare, and serious exception.

A 25-year-old male who used AAS, testosterone, and gonadotropin injections for two years developed persistent thyrotoxicosis (hyperthyroidism) that did not resolve after stopping all compounds. He remained in a thyrotoxic state for over 12 months post-cessation, with negative autoimmune markers (ruling out Graves' disease), before requiring radioactive iodine ablation (Aljaberi & Boharoon, 2019).

The proposed mechanism: supraphysiological androgens driving thyroid cell proliferation via androgen receptors on thyroid tissue. Animal studies with nandrolone decanoate showed significant increases in thyroid gland weight and altered deiodinase activity, confirming that AAS can act directly on the thyroid gland (Fortunato et al., 2006).

This is described as the first documented case of permanent AAS-induced hyperthyroidism. It is an outlier, not the norm. But it means that hyperthyroid symptoms during or after a cycle should not be dismissed.

Warning signs: unexplained resting heart rate elevation above 100 bpm at rest, heat intolerance, unintended weight loss despite adequate calories, tremor, or anxiety that appeared with cycle use and did not resolve post-cycle. If any of these persist beyond 8 weeks after your last injection, get a full thyroid panel including TSH, free T3, free T4, and a thyroid uptake scan.

Can Steroids Unmask Autoimmune Thyroid Disease?

Testosterone has documented immunosuppressive effects. A randomized trial gave testosterone undecanoate (120 mg/day) to euthyroid men with Hashimoto's thyroiditis and low testosterone. After six months, anti-TPO and anti-TG antibody titres were significantly reduced, while TSH remained stable (Krysiak et al., 2019).

The implication for AAS users: supraphysiological testosterone suppresses thyroid autoantibodies during use. If you have subclinical Hashimoto's that you do not know about, your on-cycle bloodwork will look clean. Post-cycle, when testosterone crashes to hypogonadal levels during recovery, that immunosuppressive effect lifts and autoantibodies can re-emerge. This is one more reason why baseline bloodwork before starting TRT matters.

The Levothyroxine Interaction

If you are already on thyroid replacement (levothyroxine) and start TRT or a blast, the drop in TBG frees up previously bound T4. Your fixed replacement dose effectively becomes stronger because more of it is now in the free, active form.

Symptoms of iatrogenic hyperthyroidism (palpitations, anxiety, insomnia, weight loss) can appear within weeks of starting androgens. This also affects SHBG regulation, as covered in our estradiol on TRT guide. Dose reductions of 25-50% may be needed. Recheck TSH and free T4 at 6-8 weeks after starting or stopping androgen therapy (Tahboub & Arafah, 2009).

Your Thyroid Bloodwork Checklist

What to Test

When to Test

Baseline (before cycle start): TSH + Free T4 + Free T3. This establishes your individual euthyroid baseline before AAS effects confound the picture.

Mid-cycle (weeks 5-6 for orals, weeks 6-8 for injectables): TSH + Free T4 + Free T3. Ignore total T3 and total T4. A mildly suppressed TSH with normal free hormones is expected and not a problem.

Post-cycle (4-6 weeks after last injection): TSH + Free T4 + Free T3. TBG should be largely normalized by now. TSH may be transiently elevated (the rebound phenomenon); this is normal and self-resolving.

Follow-up (8-12 weeks post-cycle): Recheck if TSH was elevated at the 4-6 week mark. If TSH is still above range at week 8 without symptoms, retest at week 12 before considering any treatment. Add anti-TPO and anti-TG if TSH remains elevated or if you have a family history of autoimmune thyroid disease.

What "Normal" Looks Like On vs. Off Cycle

Post-Cycle Thyroid Recovery

TBG Normalization: 4-6 Weeks

TBG has a circulating half-life of roughly 5 days. After stopping AAS, TBG biosynthesis resumes, and concentrations climb back to baseline over 4-6 weeks. Total T3 and T4 normalize in parallel. Alen et al. (1987) confirmed full recovery of all thyroid variables within 13 weeks of observation, though most parameters normalized sooner (Alen et al., 1987).

HPT Axis Recovery After T3 Use: 6-8 Weeks

If you used exogenous T3, the timeline is longer. TSH recovery takes roughly 16 days on average, but full pituitary responsiveness (measured by TRH stimulation) does not return until about 22 days. Free T3 and T4 responses normalize 3-6 days after TSH recovers (Krugman et al., 1975).

The official liothyronine prescribing information lists 6-8 weeks for full HPT axis recovery, which aligns with the published data.

Does PCT Affect Thyroid Recovery?

No. The hypothalamic-pituitary-thyroid axis operates independently from the hypothalamic-pituitary-gonadal axis. Clomiphene, tamoxifen, and HCG target LH, FSH, and testosterone recovery. They share no mechanism with TBG biosynthesis or pituitary thyrotroph recovery. No published study has examined whether SERM-based PCT influences thyroid recovery speed.

Your thyroid recovers on its own timeline regardless of what you are doing for PCT.

The TSH Rebound

Here is something counterintuitive: TSH can temporarily rise above the upper limit of normal during AAS withdrawal. Daly et al. (2003) administered high-dose methyltestosterone to 20 male volunteers and found that TSH increased significantly during the withdrawal phase (Daly et al., 2003).

If your post-cycle bloodwork shows a mildly elevated TSH (say, 5-7 mIU/L) at the 4-6 week mark, do not panic. Retest at 8-10 weeks. If it has normalized, no action needed. If it persists above range beyond 12 weeks, investigate further with anti-TPO and anti-TG.

Key Takeaways

• Total T3 and total T4 are unreliable on AAS. Androgens suppress TBG, which drags total values below range. This is a binding protein artifact, not hypothyroidism.
• Free T3, free T4, and TSH are the markers that matter. If all three are in range, you are euthyroid regardless of what total T3 shows.
• Oral AAS (Dianabol, Anadrol, Winstrol) hit TBG harder than injectables because of hepatic first-pass metabolism.
• AAS and corticosteroids affect the thyroid through completely different mechanisms. Do not conflate them.
• Exogenous T3 shuts down your HPT axis. Taper gradually over 2-3 weeks. Do not stop cold turkey.
• GH amplifies T4-to-T3 conversion. Reduce T3 dose accordingly if running both.
• Post-cycle TSH rebound is normal and self-resolving within 8-12 weeks. Do not start thyroid medication based on a single elevated reading.
• Steroid-induced hyperthyroidism is rare but documented. If hyperthyroid symptoms persist beyond 8 weeks post-cycle, get investigated.
• If you are on levothyroxine, recheck thyroid function 6-8 weeks after starting or stopping AAS. Your dose may need adjustment.

---

References

1. Alen, M., Rahkila, P., Reinila, M., & Vihko, R. (1987). Androgenic-anabolic steroid effects on serum thyroid, pituitary and steroid hormones in athletes. American Journal of Sports Medicine, 15(4), 357-361. PubMed

2. Aljaberi, A., & Boharoon, H. (2019). SUN-575 Anabolic steroids induced hyperthyroidism. Journal of the Endocrine Society, 3(Suppl 1), SUN-575. PMC

3. Daly, R. C., Su, T. P., Schmidt, P. J., Pagliaro, M., Pickar, D., & Rubinow, D. R. (2003). Neuroendocrine and behavioral effects of high-dose anabolic steroid administration in male normal volunteers. Psychoneuroendocrinology, 28(3), 317-331. PubMed

4. Deyssig, R., & Weissel, M. (1993). Ingestion of androgenic-anabolic steroids induces mild thyroidal impairment in male body builders. Journal of Clinical Endocrinology and Metabolism, 76(4), 1069-1071. PubMed

5. Fortunato, R. S., Marassi, M. P., Chaves, E. A., Nascimento, J. H. M., Rosenthal, D., & Carvalho, D. P. (2006). Chronic administration of anabolic androgenic steroid alters murine thyroid function. Medicine & Science in Sports & Exercise, 38(2), 256-261. PubMed

6. Fortunato, R. S., Rosenthal, D., & de Carvalho, D. P. (2007). Abuse of anabolic steroids and its impact on thyroid function. Arquivos Brasileiros de Endocrinologia & Metabologia, 51(9), 1417-1424. PubMed

7. Heyma, P., & Larkins, R. G. (1982). Glucocorticoids decrease in conversion of thyroxine into 3,5,3'-tri-iodothyronine by isolated rat renal tubules. Clinical Science, 62(2), 215-220. PubMed

8. Jonklaas, J., Burman, K. D., Wang, H., & Latham, K. R. (2015). Single-dose T3 administration: kinetics and effects on biochemical and physiological parameters. Therapeutic Drug Monitoring, 37(1), 110-118. PubMed

9. Jorgensen, J. O., Moller, J., Laursen, T., Orskov, H., Christiansen, J. S., & Weeke, J. (1994). Growth hormone administration stimulates energy expenditure and extrathyroidal conversion of thyroxine to triiodothyronine in a dose-dependent manner. Clinical Endocrinology, 41(5), 609-614. PubMed

10. Mathieson, R. A., Walberg, J. L., Gwazdauskas, F. C., Hinkle, D. E., & Gregg, J. M. (1986). The effect of varying carbohydrate content of a very-low-caloric diet on resting metabolic rate and thyroid hormones. Metabolism, 35(5), 394-398. PubMed

11. Krugman, L. G., Hershman, J. M., Chopra, I. J., et al. (1975). Patterns of recovery of the hypothalamic-pituitary-thyroid axis in patients taken off chronic thyroid therapy. Journal of Clinical Endocrinology and Metabolism, 41(1), 70-80. PubMed

12. Krysiak, R., Kowalcze, K., & Okopien, B. (2019). The effect of testosterone on thyroid autoimmunity in euthyroid men with Hashimoto's thyroiditis and low testosterone levels. Journal of Clinical Pharmacy and Therapeutics, 44(5), 742-749. PubMed

13. Olvey, D. N., Cutler, R. E., & Dowling, J. T. (1965). Thyroxine-binding by the thyroxine-binding globulin as a measure of the anabolic activity. Metabolism, 14, 891-898. PubMed

14. Small, M., Beastall, G. H., Semple, C. G., Cowan, R. A., & Forbes, C. D. (1984). Alteration of hormone levels in normal males given the anabolic steroid stanozolol. Clinical Endocrinology, 21(1), 49-55. PubMed

15. Spaulding, S. W., Chopra, I. J., Sherwin, R. S., & Lyall, S. S. (1976). Effect of caloric restriction and dietary composition on serum T3 and reverse T3 in man. Journal of Clinical Endocrinology and Metabolism, 42(1), 197-200. PubMed

16. Tahboub, R., & Arafah, B. M. (2009). Sex steroids and the thyroid. Best Practice and Research Clinical Endocrinology and Metabolism, 23(6), 769-780. PubMed

17. Thorell, J. I., Dymling, J. F., & Rannevik, G. (1979). Changes in thyroid function tests during danazol therapy. Postgraduate Medical Journal, 55(Suppl 5), 33-36. PubMed

18. Warner, B. E., Woodrow, C. J., & Pal, A. (2020). Delayed diagnosis of T3 supplementation in a bodybuilder presenting with tachycardia and features of sepsis. BMJ Case Reports, 13(1), e232867. PubMed

19. Weiss, E. P., Villareal, D. T., Racette, S. B., et al. (2008). Caloric restriction but not exercise-induced reductions in fat mass decrease plasma triiodothyronine concentrations. Rejuvenation Research, 11(3), 605-609. PubMed

20. Wilber, J. F., & Utiger, R. D. (1969). The effect of glucocorticoids on thyrotropin secretion. Journal of Clinical Investigation, 48(11), 2096-2103. PubMed